Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F. Singer(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Christoph Tinchon(LKH Hochsteiermark), Florian Fitzal, Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Angelika Pichler, Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Martin Filipits(University of Vienna), Richard Greil(Paracelsus Medical University), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Sophie Frantal(Statistics Austria), Peter Dubsky(Hirslanden Klinik St. Anna), Georg Pfeiler(Medical University of Vienna), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), Michael Hubalek(Innsbruck Medical University), Viktor Wette, P. Sevelda, Herbert Stöger(Medical University of Graz), Muy‐Kheng M. Tea(Medical University of Vienna), R. Jakesz(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 52
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k